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Richter syndrome (RS) represents the development of
high-grade lymphoma in patients with chronic lymphocytic
leukaemia (CLL) or small lymphocytic lymphoma (SLL)
and presents a diagnostic and therapeutic challenge with
an adverse prognosis. The genetic background and
morphology of RS in CLL patients treated with chemo-
immunotherapy is extensively characterised; however, our
knowledge about RS in patients treated with targeted oral
therapies should be extended.
To understand the morphologic and molecular changes
leading to RS in CLL patients treated with the Bruton’s
tyrosine kinase inhibitor, ibrutinib, and the BCL2 inhibitor,
venetoclax, sequential samples from six CLL/SLL patients
undergoing RS were collected in both the CLL and RS
phases.
A detailed immunophenotypic analysis of formalin-fixed,
paraffin-embedded tissue specimens of RS phase was
performed, followed by extensive molecular characterisa-
tion of CLL and RS samples, including the immunoglobulin
heavy chain gene (IGH) rearrangement, TP53 mutations,
drug-induced resistance mutations in BTK and BCL2
genes and various copy number changes and point mu-
tations detectable with multiplex ligation-dependent probe
amplification (MLPA).
Rare, non-diffuse large B-cell lymphoma phenotypes of
RS were observed in 3/6 cases, including plasmablastic
lymphoma and a transitory entity between diffuse large B-
cell lymphoma and classical Hodgkin lymphoma. The
majority of cases were clonally related and harboured an
unmutated variable region of the immunoglobulin heavy
chain gene. Abnormalities affecting the TP53 gene
occurred in all patients, and every patient carried at least
one genetic abnormality conferring susceptibility to RS. In
the background of RS, 2/5 patients treated with ibrutinib
showed a BTK C481S resistance mutation. One patient-3025/Online ISSN 1465-3931 © 2021 The Authors. Publ
is an open access article under the CC BY-NC-ND license
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ticle as: Gángó A et al., Morphologic and molecular analysis of
toclax, Pathology, https://doi.org/10.1016/j.pathol.2021.04.008developed a BCL2 G101V mutation leading to venetoclax
resistance and RS.
In conclusion, our findings contribute to better under-
standing of RS pathogenesis in the era of targeted oral
therapies. Rare phenotypic variants of RS do occur under
the treatment of ibrutinib or venetoclax, and genetic factors
leading to RS are similar to those identified in patients
treated with chemoimmunotherapy. To our best knowl-
edge, we have reported the first BCL2 G101V mutation in
an RS patient treated with venetoclax.
Key words: Chronic lymphocytic leukaemia; Richter syndrome; ibrutinib;
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Richter syndrome (RS) represents the development of high-
grade lymphoma in the setting of an antecedent or concom-
itant chronic lymphocytic leukaemia (CLL) or small lym-
phocytic lymphoma (SLL).1 Histologically, two main types
of RS are distinguished, diffuse large B-cell lymphoma
(DLBCL) and classical Hodgkin lymphoma (cHL), with the
former entity comprising the majority (80–90%) of cases.1
Rarely, transformation to plasmablastic lymphoma (PBL),
histiocytic sarcoma, lymphoblastic lymphoma and interdigi-
tating dendritic cell sarcoma may occur.2 The DLBCL type of
RS appears as confluent sheets of large, CD20+ neoplastic B
cells with a variable positivity of markers characteristic for
the preceding CLL.3 The vast majority (90–95%) of DLBCL
type RS cases exhibit a non-germinal centre phenotype
(CD10– , MUM1/IRF4+).3–5 The cHL variant of RS is
characterised by CD30+/CD15+/CD20– phenotype, with
Hodgkin and Reed–Sternberg cells located in the cHL-
specific inflammatory background of T cells, histiocytes,ished by Elsevier B.V. on behalf of Royal College of Pathologists of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CLL cases Hodgkin-like cells with CD30+ expression are in
the background of small CLL lymphocytes instead of the
reactive cellular milieu of cHL, which is not considered as a
‘true’ transformation.6,7
Clonal relatedness is the most important prognostic factor
in RS and represents a true transformation in contrast to
clonally unrelated lymphomas developing in patients with
CLL. While ~80% of DLBCL-RS is clonally related to the
antecedent CLL based on IGHV-D-J rearrangement, only
40–50% of the cHL-RS arises in a clonally related manner.8
RS may develop in patients carrying either mutated or
unmutated IGHV; however, in most of the cases only the
latter represents a clonally related transformation.9 Although
the term ‘clonally unrelated RS’ is being used widely, these
cases are biologically de novo lymphomas with higher
response rates to therapy and more favourable prognosis
compared to their clonally related counterparts.3–5 Patients
with clonally unrelated DLBCL-RS have a median survival
of ~5 years, in contrast to the much poorer outcome in
clonally related DLBCL-RS (8–16 months).5 The outcome
of HL-RS patients is more favourable compared to DLBCL-
RS, but worse than that of the primary classical HL.10 RS
developing in patients treated with novel targeted therapies
confers a highly adverse prognosis, with only 13% of patients
achieving remission.11,12
Over the past years several molecular alterations connected
with the development of DLBCL-RS have been identified.
Risk factors associated with the high-grade transformation of
CLL comprise hereditary single nucleotide polymorphisms
(SNP), somatically acquired genetic lesions and clinical
features. Hereditary SNPs including BCL2 rs4987852, CD38
rs6449182 and LRP4 rs2306029 predisposing to RS confer a
moderate risk via incompletely understood functional
mechanisms.13–15 Cases of CLL carrying an unmutated
IGHV gene are prone to transform into RS, especially when
harbouring the IGHV4-39 gene solely or as a part of the
stereotyped B-cell receptor subset #8.4 CLL patients with
NOTCH1 mutation exhibit a 10-fold higher probability of
developing RS compared to their NOTCH1 wild-type coun-
terparts.16–18 TP53 defects (mutations or 17p deletion) are
present in 60% of RS patients, acquired mainly at trans-
formation.5 Various genetic events affecting MYC and
CDKN2A genes lead to their deregulation and are acquired at
the time of transformation.5,19–21 Among clinical features,
advanced stage (Rai III-IV) and a lymph node size >3 cm are
the only factors associated with transformation.22–24 Pre-
dictive markers of CLL progression [decrease in lymphocyte
doubling time, bone marrow involvement, elevated b2-
microglobulin and elevated lactate dehydrogenase (LDH)
level] are not associated with RS development, suggesting a
biologically distinct way of CLL progression and trans-
formation.24,25 Several studies have investigated the impact
of the therapy on development of RS. Exposure to fludar-
abine, a widely used purine analogue was found to be asso-
ciated with increased risk of RS in some series,26 although
not in others.25,27
Small molecule inhibitors targeting the B-cell receptor
(BCR) pathway (especially ibrutinib) and Bcl2 related
apoptosis pathway (venetoclax) have recently revolutionised
the therapy of CLL, conferring remarkable outcomes in
high-risk as well as in relapsed/refractory patients.28–31 InPlease cite this article as: Gángó A et al., Morphologic and molecular analysis of
ibrutinib or venetoclax, Pathology, https://doi.org/10.1016/j.pathol.2021.04.008spite of the remarkable results, a proportion of patients un-
dergo progression or Richter transformation (RT) due to the
emergence of resistance mutations or additional genetic ab-
normalities.32,33 However, our knowledge about the genetic
changes leading to RT in CLL patients treated with novel
targeted therapies is incomplete and should be further
elucidated.
In this study, we aimed to scrutinise the histological and
molecular background of RS in six ibrutinib and/or veneto-
clax treated patients who underwent high-grade trans-
formation, to gain a better insight into the process leading to
the diagnostically and therapeutically challenging phenome-
non of RS.
PATIENTS AND METHODS
The study was conducted in accordance with the Declaration of Helsinki and
approved by the Ethics Committee of the Medical Research Council in
Hungary.
Sequential samples from six CLL/SLL patients undergoing RT were
collected in the CLL phase and at RS diagnosis except for Patient 4 (P4)
from whom only a single RS sample was available (although basic cyto-
genetic characterisation had been performed). The patient cohort consisted
of one female and five male patients, their median age at CLL diagnosis
was 58 years (38–75 years), and the median follow-up time was 109.5
months (53–355 months). Four patients were treated with ibrutinib, and
one patient with venetoclax and ibrutinib+venetoclax combination,
respectively. Median time from the initiation of targeted therapy to RT was
20.0 months (2–52 months), the median survival following RT was 1.5
months (0–29 months). Additional clinical data are presented in Table 1
and Fig. 1.
Morphologic and immunophenotypic analysis of RS samples was carried
out using formalin-fixed, paraffin-embedded (FFPE) tissue specimens.
CD19+ lymphocytes were purified from peripheral blood and bone marrow
aspirate with EasySep Human CD19 Positive Selection Kit II (StemCell
Technologies, Canada) and DNA was isolated using AllPrep DNA/RNA/
miRNA Universal Kit (Qiagen, Germany). DNA isolation from FFPE tissues
was performed with QIAamp DNA FFPE Tissue Kit (Qiagen). After fluori-
metric quantification we performed IGHV-IGHD-IGHJ sequencing, next-
generation sequencing (NGS) of the TP53 gene, multiplex ligation-
dependent probe amplification (MLPA) targeting relevant abnormalities in
CLL and droplet digital polymerase chain reaction (ddPCR) for the detection
of resistance mutations against targeted therapies.
The analysis of IGHV-IGHD-IGHJ rearrangements was performed as
described by Agathangelidis et al.34 DNA amplification with leader primers
was followed by bidirectional Sanger sequencing and results were obtained
by immunoinformatic analysis using IMGT V-QUEST and ARResT/
AssignSubsets software in concordance with the updated ERIC recommen-
dations.35 The whole coding region of TP53 gene including the splice sites
was analysed using the SureMASTR TP53 library preparation kit (Agilent,
USA) and MiSeq sequencing with a minimum mean coverage of 10,000×.
The pathogenicity of TP53 variants was determined using the Seshat tool
(https://p53.fr/tp53-database/seshat). Multiplex ligation-dependent probe
amplification (MLPA) with SALSA P037 and P038 CLL-specific probemixes
(MRC-Holland, The Netherlands) was performed to detect various copy
number changes and mutations of great importance in CLL (including de-
letions of chromosomes 11q, 13q, 17p, trisomy of chromosome 12, and
NOTCH1 c.7541_7542delCT, SF3B1 K700E andMYD88 L265P mutations),
following the manufacturer’s instructions. Resistance mutations in BTK and
BCL2 genes were analysed using ddPCR method with mutation specific
assays for the detection of the most frequent variants (BTK C481S,
dHsaMDS802598840; BCL2 G101V wild-type, dHsaADS52164188; BCL2
G101V mutant type, dHsaADS26433961; BCL2 D103Y wild-type,
dHsaADS13624642; BCL2 D103Y mutant type, dHsaADS77894415).
Droplet generation and reading was performed using QX200 AutoDG
Droplet Digital PCR System (Bio-Rad, USA). The mean sensitivity of the
method was 0.01%.Richter syndrome in chronic lymphocytic leukaemia patients treated with
Table 1 Patient characteristics
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P2 F 48 62 178 180 FC, ofa, R-FC, R-CHOP, R-B, IBR,
R-IBR-VEN
DLBCL
P3 M 49 59 123 126 FC, R-CHOP, B, B, Chl, ofa, duve, IBR
(only for 3 w),CHOP, COPP/ABV +
irradiation (for cHL), IBR
DLBCL
P4 M 67 74 92 93 R-FC, R-B, IBR DLBCL
P5 M 75 78 41 70 IBR DLBCL/cHL
P6 M 75 79 52 53 R-CVP, CHOP, R, alem, R-B, IBR Plasmablastic lymphoma
alem, alemtuzumab; B, bendamustine; Chl, chlorambucil; cHL, classical Hodgkin lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisolone;
CLL, chronic lymphocytic leukaemia; COPP/ABV, cyclophosphamide, vincristine, prednisone and procarbazine/doxorubicin, bleomycin and vinblastine; DLBCL,
diffuse large B-cell lymphoma; duve, duvelisib; F, female; FC, fludarabine, cyclophosphamide; FCM, fludarabine, cyclophosphamide, mitoxantrone; Flu,
fludarabine; IBR, ibrutinib; M, male; ofa, ofatumumab; R, rituximab; R-B, rituximab, bendamustine; R-Chl, rituximab, chlorambucile; R-CHOP, rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisolone; R-CVP, rituximab, cyclophosphamide, vincristine, prednisolone; R-FC, rituximab, fludarabine,
cyclophosphamide; RS, Richter syndrome; VEN, venetoclax; w, weeks.
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Morphologic patterns of transformation
All diagnoses for this study were rendered by two indepen-
dent expert haematopathologists. Three of the six Richter
syndrome cases (P2, P3 and P4) were diagnosed as DLBCL
showing diffuse proliferation of neoplastic large B lympho-
cytes with a markedly increased Ki-67 proliferation activity
(Table 1).
RS of P1 presented 5 months after venetoclax initiation as
a paravertebral mass causing low back pain. The histologicalFig. 1 Timeline and main clinical features of chronic lymphocytic leukaemia (CLL) pat
left part of the graph illustrates the clinical course of patients from diagnosis to ibrutini
treatment (TTFT) while numbers below represent time to ibrutinib initiation in months
before transformation. Before long-term ibrutinib therapy, P3 received ibrutinib for 3 w
simultaneously with CLL and therefore received cHL-directed chemotherapy as well.
Please cite this article as: Gángó A et al., Morphologic and molecular analysis of
ibrutinib or venetoclax, Pathology, https://doi.org/10.1016/j.pathol.2021.04.008examination of the core biopsy specimen revealed a tumour
mass with a diffuse pattern composed of polymorphic large
cells. The sample was tested with a wide range of immuno-
histochemical markers. The tumour cells were positive for
LCA/CD45 (partial), MUM1, p53, S100 and CD4 stainings
with partial Oct-2 and Fascin-1 positivity and a proliferation
activity of 60% by Ki-67. The following markers proved to
be negative: CD20, PAX5, CD79a, CD21, CD23, Bcl-6,
CD10, CD138, CD30, CD3, CD5, CD7, PD-L1, CD68,
ALK1, kappa, lambda, CD15 and melanoma markers
(MelanA, HMB45 and SOX10). Based on the partial LCAients developing Richter syndrome during ibrutinib or venetoclax treatment. The
b initiation with lines of therapies. Numbers above the line indicate time to first
. Patient 2 (P2) received ibrutinib and venetoclax simultaneously for 12 months
eeks, but discontinued due to drug intolerance. P3 developed classical HL
BM, bone marrow; LN, lymph node; PB, peripheral blood.
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Fig. 2 Richter transformation of chronic lymphocytic leukaemia (CLL) into null-phenotype high-grade lymphoma presented as a paravertebral mass, Patient 1. (A) The
neoplastic large cells have lobulated nuclei and prominent nucleoli (H&E), (B) are of haematopoietic origin (LCA), and show negativity of (D) CD20 and (E) CD30. (C)
CD5-positive CLL cells are scattered within the population of large cells. (F) The proliferation activity is approximately 60% (Ki-67).
4 GÁNGÓ et al. Pathology (xxxx), xxx(xxx), -and Oct-2 expression, the strong Ki-67 positivity, and the
lack of more lineage specific markers (B-cell, T-cell markers,
lack of CD30), the initial diagnosis of ‘null phenotype’ high-
grade lymphoma with a morphology resembling Hodgkin
lymphoma or anaplastic large cell lymphoma was estab-
lished, which was later confirmed to be of B-cell origin with
monoclonal IgH gene rearrangement (Fig. 2).
P5 experienced a clinically suspicious right inguinal lymph
node enlargement 2 months after initiating ibrutinib, concur-
rently with lymph node regression in other localisations.
Histological examination of the core biopsy specimen
revealed a diffuse lymphoid infiltrate, and besides small
lymphocytes, it consisted mainly of atypical, CD20 and CD30
positive large cells. A proportion of the large cells proved to
be multinucleated giant cells. The small cell component
showed strong CD5 and weak CD20 positivity. The
neoplastic large cells showed a partial expression of C-MYC,
a proliferation activity of 60% by Ki-67 and MUM1 expres-
sion of 100%, with negative Bcl-6 staining. Genomic DNA of
Epstein–Barr virus (EBV) was not detectable by real-time
PCR. In summary, both the morphology and immunopheno-
type of the large cell component showed mixed features be-
tween classical Hodgkin lymphoma and non-germinal centre
type DLBCL (Fig. 3).
After 18 months of ibrutinib treatment, P6 showed multiple
gingival proliferations which were excised for histological
evaluation. Wide subepithelial sheets of tumour cells were
observed, and the proliferation activity was approximately
90% as determined by Ki-67 staining. The tumour cells
showed marked LCA, CD79a, CD138 and kappa light chain
positivity, while CD20, CD3, CD30, MPO and Pan-CK
stainings were negative. Based on this immunophenotype,
the diagnosis of plasmablastic lymphoma was established inPlease cite this article as: Gángó A et al., Morphologic and molecular analysis of
ibrutinib or venetoclax, Pathology, https://doi.org/10.1016/j.pathol.2021.04.008the patient, without previous immunodeficiency, that is not
associated with CLL or CLL-related therapies (e.g., HIV
infection) (Fig. 4).
Genetic background of transformation
Clonal relationship determined by the IGHV-D-J
rearrangement
IGHV analysis was successful in four of six CLL-RS paired
samples. Three of the four successfully analysed sample pairs
were clonally related (3/6 patients overall), with IGHV muta-
tional status and IGHV-D-J genes being identical. Further
details of IGHV-D-J mutation analysis are shown in Table 2.
Chromosome 17p deletions and TP53 mutations
Abnormalities affecting the key cell cycle regulator TP53
occurred in all patients. TP53 abnormalities were present in
all CLL samples and four of six RS samples. Detailed results
of TP53 analysis are shown in Fig. 5 and Table 3.
Other genetic aberrations and clinical correlations
13q deletion proved to be the second most frequent chro-
mosomal aberration with three of six affected cases,
followed by trisomy 12 (2 affected cases). The chromosomal
abnormalities occurred in various constellations and were
mainly monoallelic (Fig. 5). Using the SALSA P038 CLL-2
probemix, we were able to investigate the presence of three
mutations frequently occurring in CLL [SF3B1 c.2098A>G
(p.K700E), NOTCH1 c.7541_7542delCT (p.P2514fs) and
MYD88 c.794T>C (p.L265P)]. Although cases carrying tri-
somy 12 are frequently accompanied by NOTCH1 muta-
tions, these two aberrations predisposing to RS occurredRichter syndrome in chronic lymphocytic leukaemia patients treated with
Fig. 3 Richter transformation of chronic lymphocytic leukaemia (CLL) into mixed phenotype B-cell lymphoma with features of diffuse large B-cell lymphoma and
classical Hodgkin lymphoma in an inguinal lymph node (Patient 5). (A) The diffuse lymphoid infiltrate effaces the original structure of the lymph node (H&E). (B) The
anaplastic large cell component mixed with the remnant CLL cells (CD5) is positive for (C) CD20, (D) CD30, and (E) C-MYC. (F) The proliferation activity is
approximately 60% (Ki-67).
Fig. 4 Richter transformation of CLL into plasmablastic lymphoma (PBL) manifested in the oral mucosa (Patient 6). (A) The neoplastic cells show an immunoblastic
morphology with several mitoses (H&E). (B) The plasmablastic/plasmacytic differentiation is characterised by CD20 negativity and (C) CD138 positivity among other
markers. (D) Monoclonal tumour cells show kappa light chain positivity and (E) lambda negativity. (F) The proliferation activity of PBL cells is 90% (Ki-67).
RICHTER SYNDROME IN IBRUTINIB/VENETOCLAX-TREATED CLL 5independently in our cohort. Interestingly, P2 proved to be
the sole patient to harbour a 9p21.3 deletion, leading to
CDKN2A and CDKN2B loss in both CLL and RS phases.
Further details are shown in Fig. 5.Please cite this article as: Gángó A et al., Morphologic and molecular analysis of
ibrutinib or venetoclax, Pathology, https://doi.org/10.1016/j.pathol.2021.04.008There were remarkable differences among the clinical
features of the patients in our cohort, many of which may be
linked to certain genetic alterations. P2 carried the largest
number of aberrations (6 lesions in CLL and 10 lesions in RSRichter syndrome in chronic lymphocytic leukaemia patients treated with
Table 2 Clonality analysis
Patient ID Immunoglobulin heavy chain (CLL) Immunoglobulin heavy chain (RS) RS clonality
M/U V D J CDR3 Subset M/U V D J CDR3 Subset
P1 M IGHV4-34*01 F IGHD6-13*01 F IGHJ6*02 F 14 Unassigned M IGHV1-18*01 F IGHD2-2*01 F IGHJ6*02 F 20 Unassigned Unrelated
P2 U IGHV3-74*01 F IGHD5-12*01 F IGHJ6*02 F 16 Unassigned U IGHV3-74*01 F IGHD5-12*01 F IGHJ6*02 F 16 Unassigned Related
P3 U IGHV3-33*01 F,
IGHV3-33*06 F
IGHD6-13*01 F IGHJ6*02 F 23 Unassigned U IGHV3-33*01 F,
IGHV3-33*06 F
IGHD6-13*01 F IGHJ6*02 F 23 Unassigned Related
P4 No data U IGHV3-23*01 F,
IGHV3-23D*01 F
IGHD1-26*01 F IGHJ4*02 F 22 Unassigned NA
P5 U IGHV1-69*01 F,
IGHV1-69*01D F
IGHD3-16*02 F IGHJ3*02 F 21 CLL#6 U IGHV1-69*01 F,
IGHV1-69*01D F
IGHD3-16*02 F IGHJ3*02 F 21 CLL#6 Related
P6 U IGHV1-3*01 F IGHD6-19*01 F IGHJ4*02 F 13 CLL#1 No data NA
CDR3, complementarity determining region 3; CLL, chronic lymphocytic leukaemia; D, diversity; J, joining; M, mutated; NA, not applicable; RS, Richter syndrome; U, unmutated; V, variable.
Table 3 TP53 mutations identified in the paired samples
Patient ID TP53 mutation (CLL) TP53 mutation (RS)
cDNA change Amino acid change VAF (%) COSMIC ID Clinical significance cDNA change Amino acid change VAF (%) COSMIC ID Clinical significance
P1 c.533delA p.H178Pfs*69 1.8% COSM6960219 Deleterious Negative
c.533delinsCC p.H178Pfs*3 1.3% Novel Probably deleterious
c.536A>G p.H179R 3.2% COSM10889 Pathogenic
c.713G>A p.C238Y 1.6% COSM11059 Pathogenic
c.814G>A p.V272M 22.0% COSM10891 Pathogenic










P3 c.472C>G p.R158G 4.6% COSM11087 Deleterious c.517G>T p.V173L 1.6% COSM43559 Pathogenic
c.503A>G p.H168R 2.1% COSM43545 Deleterious
c.652_654delGTG p.V218del 3.7% COSM6496 VUS
c.747G>T p.R249S 12.0% COSM10817 Pathogenic
P4 No data c.466C>G p.R156G * COSM45154 Probably deleterious
P5 Negative c.584T>C p.I195T * COSM11089 Pathogenic
P6 c.771_777delGGAAGAC p.E258Pfs*85 8.5% Novel Probably deleterious Negative
VAF, variant allele frequency; VUS, variant of unknown significance; *, samples analysed by Sanger sequencing outside of the setting of this study.
VAF must be over the 20% sensitivity of Sanger sequencing, but its exact value is unknown.
















































RICHTER SYNDROME IN IBRUTINIB/VENETOCLAX-TREATED CLL 7phase), resulting in a complex karyotype and genomic
instability leading to a highly aggressive large cell trans-
formation of CLL resembling acute leukaemia. P1 harbour-
ing 13q del and IGHV-M (germline homology of 96.14%)
was observed for 12 years after diagnosis with no need of
treatment, and RS proved to be clonally unrelated due to the
use of different IGH genes, but still being IGHV-M (germline
homology of 93.51%). Although trisomy 12 confers an in-
termediate prognosis, the unmutated IGHV gene with the
PBL phenotype and the presence of stereotyped BCR subset
#1 may lead to a particularly dismal outcome as documented
in the case of P6. The total follow-up time (53 months) of P6
is the shortest in our cohort; the patient had to be treated
immediately after diagnosis and PBL transformation
occurred 18 months after ibrutinib initiation (Fig. 1). P1 and
P6 succumbed to RS after a total follow-up time of 355 and
53 months, respectively (Fig. 1).
P5 harboured an adverse SF3B1 mutation with a VAF of
3% and an IGHV-U genotype. Although generally stereo-
typed BCRs confer a less favourable outcome in the IGHV-U
patients, subset #6 carried by P5 did not have such a negative
impact on survival as subset #1 in P6. At transformation, P5
continued ibrutinib therapy with the addition of 6 cycles of
rituximab-bendamustine and is still in remission 29 months
after developing clonally related RS (follow-up 70 months).Fig. 5 Heat map displaying the IGHV mutational status, chromosomal aber-
rations and mutations identified across the six patients. Chronic lymphocytic
leukaemia (CLL) sample from Patient 4 (P4) was not available. NA (not
applicable) denotes absent data due to sample unavailability, unsuccessful or
unreasonable analysis (e.g., BCL2 analysis in venetoclax-naïve patients).
Please cite this article as: Gángó A et al., Morphologic and molecular analysis of
ibrutinib or venetoclax, Pathology, https://doi.org/10.1016/j.pathol.2021.04.008Ibrutinib/venetoclax resistance mutations
Two of five RS samples analysed showed a BTK C481S
ibrutinib resistance mutation (P4 and P2). One patient carried
a BCL2 G101V venetoclax resistance mutation (P2), the RS
sample of the other patient undergoing venetoclax therapy
(P1) was not available in the required amount for ddPCR
analysis. P4 developed a BTK C481S mutation with a variant
allele frequency (VAF) of 0.21% that was detectable in the
RS phase 22 months after ibrutinib initiation. P2 was treated
with ibrutinib until she progressed 40 months after initiating
ibrutinib. After progression, venetoclax and rituximab were
added to ibrutinib and this combination was administered for
12 months until RT occurred. CLL sample of P2 was
collected at progression and showed a BTK C481S mutation
with a VAF of 11.9%. One year later, at the time of trans-
formation, the BTK C481S VAF decreased to 0.95% while
the BCL2 G101V mutation emerged with a VAF of 4.6%.
DISCUSSION
The BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax
have revolutionised the treatment of CLL over recent years,
especially in the setting of relapsing/refractory or TP53
mutated disease. However, clonal evolution initiated by
conventional chemoimmunotherapy continues under the se-
lective pressure exerted by targeted therapies, and drives
progression, relapse and transformation. RS developing
under chemoimmunotherapy was studied excessively, but the
genetic and morphologic characterisation of ibrutinib- or
venetoclax-induced RT needs further elucidation.
Although our knowledge is rapidly growing on the mo-
lecular and radiological features of RS, histological exam-
ination has an outstanding impact on diagnosis
establishment and the morphology correlates frequently
with molecular and clinical features. In the era of cytotoxic
therapies, CLL transformation to PBL occurred extremely
rarely.36 However, in a cohort of four post-ibrutinib RS
cases reported by Chan et al., 50% of the patients showed
PBL morphology,37 and a further similar case was reported
by others.38 The molecular mechanism underlying PBL
transformation of ibrutinib treated CLL is unclear. Most of
the PBL cases are extranodal and arise de novo in associ-
ation with immunodeficiency or EBV positivity. Secondary
cases show monoclonal IGH39 and MYC rearrangement,40
and cases with trisomy 12 have also been reported41
similar to our P6. Considering that BTK is downregulated
in plasma cells,42 plasmablastic transformation of ibrutinib
treated CLL may be an escape mechanism to overcome
BTK inhibition37 without developing a resistance mutation.
In line with this theory, P6 in our cohort underwent RT
characterised by PBL morphology without the canonical
BTK C481S resistance mutation, similarly to three previ-
ously published cases.37,38
The development of ibrutinib resistance mutations in BTK
and PLCG2 genes is the leading cause of CLL progres-
sion.38,43 RS during ibrutinib treatment occurs in 5.0–7.3%
of patients within 17–24 months after ibrutinib initiation, as
reviewed by Lampson et al.44 The mean period (20 months)
from ibrutinib start to RT in our cohort is in line with these
findings. BTK or PLCG2mutations occur in ~80% of patients
with CLL progression, but in only ~40% of RS cases.45,46
This difference may be explained by the underestimated
mutation frequency because of the limited availability of RSRichter syndrome in chronic lymphocytic leukaemia patients treated with
8 GÁNGÓ et al. Pathology (xxxx), xxx(xxx), -tissues compared to peripheral blood, or more likely by
biologically distinct ways of CLL progression and RS. In our
cohort, two of five patients harboured a BTK C481S mutation
among those who underwent RT during ibrutinib treatment.
This prevalence corresponds to the literature; however, we
should note that non-C481S BTK mutations or PLCG2 mu-
tations were not analysed in this study.
RS during venetoclax therapy occurred in two patients in
our cohort 8.5 months after therapy initiation. Interestingly,
the high frequency of RS observed in heavily pretreated pa-
tients47 may not correspond to the frequency of RS in a less
heavily pretreated cohort.48 Refractoriness to fludarabine and
complex karyotype are the main risk factors of early pro-
gression in venetoclax treated patients,11 the latter presum-
ably being responsible for the early RS and aggressive
clinical course of P2 in our cohort. Acquired abnormalities in
the BTG1, TP53, CDKN2A/B, SF3B1 and BRAF genes have
been reported in the background of CLL progression and RS
in venetoclax-treated patients.49 To our best knowledge,
BCL2 mutations have not yet been reported in RS;50 there-
fore, this study might be the first to reveal a BCL2 G101V
resistance mutation in RS developing during venetoclax
therapy. However, as remnant CLL clones were observed
besides the DLBCL component in the patient’s bone marrow
biopsy, a CLL origin of BCL2 G101V mutation could not be
excluded.
Given that some genetic lesions present in CLL phase were
absent in RS phase, they could have been replaced by CLL
subclones with a higher potential towards transformation.
Indeed, 13q deletion observed in CLL phase of P3 has been
eliminated, while an SF3B1 K700E mutation predisposing to
RS emerged. Furthermore, subclonal dynamics affecting
TP53 mutations has also been detected. All six patients car-
ried TP53 defect (17p deletion, TP53 mutation or both). In
line with our previous findings in ibrutinib-treated CLL,43 the
majority of TP53 mutated subclones have been eliminated
under the selective pressure of ibrutinib. In the CLL phases of
P1 and P6, six TP53mutations were identified altogether, and
all of them were absent in the RS phase. The four TP53
mutations of the CLL sample of P3 were replaced with only
one mutation detected in the RS phase.
In summary, our findings support the importance of
morphologic and molecular analysis in Richter trans-
formation of CLL in the era of oral targeted therapies. Since
all patients except for one had received multiple lines of
cytotoxic chemotherapy before initiating targeted therapies,
the morphologic and genetic changes observed do not
necessarily represent the features of cytotoxic therapy-naïve
RS patients. Every patient in our cohort carried at least one
genetic aberration conferring susceptibility to RS, with the
predisposing factors in ibrutinib/venetoclax-treated patients
being the same as identified in patients treated with chemo-
immunotherapy (unmutated IGHV, stereotyped BCRs, TP53
defect, trisomy 12, CDKN2A/B loss, MYC aberrations,
NOTCH1 and SF3B1 mutations). BTK or BCL2 mutations
play a less prominent role in RS pathogenesis compared to
CLL progression or relapse. To our best knowledge, we have
reported the first BCL2 G101V mutation in an RS patient
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